Carregant...
Pazopanib in sarcomas: expanding the PALETTE
PURPOSE OF REVIEW: After failure of standard therapy, few effective treatment options exist for adult patients with metastatic sarcomas, and median survival remains dismal at approximately 1 year. Pazopanib, a multitargeted tyrosine kinase inhibitor, has recently been approved for nonadipocytic soft...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4090026/ https://ncbi.nlm.nih.gov/pubmed/23666473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0b013e3283622d3a |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|